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Letters to the EditorSAFETY OFAPROTININ IN
ADULT CARDIAC
SURGERY: REVISITING THE
VALIDITY OFA MIXED-
TREATMENT COMPARISON
META-ANALYSIS
To the Editor:
I read with great interest the
article by Howell and colleagues1 on
a mixed-treatment meta-analysis of
trials of aprotinin in adult cardiac sur-
gery drawn from the publications iden-
tified in a previous Cochrane review.2
In their publication, Howell and col-
leagues1 concluded that this reanalysis
demonstrated no increase in the risk of
mortality for patients treated with
aprotinin relative to either placebo or
other antifibrinolytic agents.
Recently, a variety of sophisticated
statistical methods have been pro-
posed to provide direct and indirect
estimates of comparative treatment
effects. Such evidence synthesis ap-
proach can be informative when rela-
tive treatment effects are consistent
across all trials and there is high
agreement between direct and indirect
estimates. To achieve relevant clinical
impact, however, the validity of
methods must convince both the epi-
demiologic and clinical audiences. I
believe that the limitations described
here question the validity of the pub-
lished results1 and thus their utility
in guiding medical decision making.
First, Howell and colleagues1 did
not adequately discuss the statistical
models (and their limitations) for esti-
mating indirect and mixed-treatment
comparisons, implying that they could
provide more accurate and precise re-
sults than direct pairwise compari-
sons. Indirect and mixed-treatment
comparisons are based on assump-
tions of transitivity (if A is much bet-
ter than B, and B is better than C, then
A is assumed to be better than C) and
consistency (agreement between vari-
ous sources of evidence), assumptions
that can be verified conceptually and
epidemiologically but are, however,
subject to substantial uncertainty.610 The Journal of Thoracic and CConsideration of these aspects will
naturally lead clinicians and system-
atic reviewers in evaluating the under-
lying assumptions, will encourage
exploration of potential disagree-
ments between trials thus giving better
insight into the research question, and
will add transparency to the choices
being made regarding comparative
data synthesis.3
Second, bias in small trials of antifi-
brinolytics is notorious, and often
selective reporting is intractable. Vari-
ous approaches to deal with publica-
tion bias and to account for effect
modifiers or to evaluate the risk of
bias have been developed.3 Indeed,
the reporting bias effect in mixed-
treatment comparisons may differ
from that in conventional meta-analy-
ses.4 Howell and colleagues1 failed
to mention, however, that the Co-
chrane review2 they used for their
mixed-treatment comparisons noted
evidence of publication bias in trials
testing aprotinin. This led to a probable
overestimation of the blood-sparing
effect of the drug, thus bringing into
question the results provided in Fig-
ure 5 in the article of Howell and col-
leagues.1 Conversely, no publication
bias was reported in relation to clinical
outcomes of death,2 but a trend was
seen toward increased mortality
among those patients receiving aproti-
nin relative to those who received tra-
nexamic acid or ε-aminocaproic acid.
Third, I believe that the main lim-
itation of the meta-analysis by
Howell and colleagues is the rela-
tively small number of deaths (highly
dependent on the Blood Conservation
Using Antifibrinolytics in a Random-
ized Trial [BART] study), which
clearly limits the power of the analy-
ses. Along the same line, antifibrino-
lytic trials have been conducted for
different durations, explaining the
variation in amounts of evidence as
a result of variations across trials in
characteristics of cardiac patients,
surgical procedures, or outcome as-
sessment5 (eg, mortality duringardiovascular Surgery c February 2013surgery, in-hospital mortality, 30-
day mortality).
In summary, I believe that Howell
and colleagues have unintentionally
overinterpreted the evidence and
ignored assumptions inherent in
mixed-treatment meta-analysis. This
has led to overly categoric conclu-
sions from an interesting approach
fraught with uncertainty.
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